tofacitinib oral solution

CP 690,550 oral solution (tofacitinib oral solution) is a liquid formulation of tofacitinib, a small molecule Janus kinase (JAK) inhibitor developed by Pfizer. Tofacitinib selectively inhibits JAK1 and JAK3, thereby blocking the signaling of several inflammatory cytokines (such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21) that are integral to lymphocyte activation, proliferation, and function. The oral solution formulation, marketed under the brand name Xeljanz, was developed to provide an easier-to-administer oral option for pediatric patients and individuals who have difficulty swallowing tablets. It is FDA-approved for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) and juvenile psoriatic arthritis (jPsA) in patients 2 years of age and older, and has been evaluated in clinical studies for its palatability and pharmacokinetics.

Brand names

XeljanzXeljanz Oral Solution

Other names

CP 690,550 oral solutionCP 690,550 oral solutionsCP-690,550 oral solutionCP-690,550 oral solutionstasocitinib oral solutiontasocitinib oral solutionstofacitinib oral solutions